文献速递临床试验与 GCP基础与转化研究

平台试验实践:在正在进行的FLAIR确证性试验中新增实验性研究组

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia.
PubMed 文献 · Trials · 2021-01-08

FLAIR是一项针对慢性淋巴细胞白血病的随机、对照、开放标签、确证性平台试验,原设计需754例患者。试验在不停招募的情况下成功修订,新增一个实验组和一个对照组,总样本量将达1516例,从而加速评估新兴实验性疗法,显著缩短主要结局时间且不损害研究有效性。

要点

  • 平台设计允许在持续招募中无缝新增或停止治疗组,无需暂停试验。
  • 通过同期对照、控制I型错误率及跨阶段分析方法确保结果无偏。
  • 该策略节省资源并提前数年在新药确证性试验中评估新兴疗法。

核心结论

  • FLAIR试验证明可在现有确证性试验框架内评估新兴实验性疗法,而不损害试验实施、报告或有效性。

研究设计与样本

  • FLAIR为随机、对照、开放标签、确证性平台试验,原设计两臂需754例患者。
  • 第2阶段新增一个实验组和一个对照组,第3阶段原实验组因达到计划招募目标而关闭,总计将随机分配1516例参与者。

主要发现

  • 协议修订和随机化调整在不停招募的情况下无缝完成。
  • 统计考量包括使用同期对照以应对阶段效应、适当控制I型错误率及考虑跨阶段分析方法,经同行评审及多个委员会批准。

临床怎么用

  • 该策略可在现有试验中快速评估新兴疗法,节省资源并提前数年获得确证性证据。

局限性

  • 尽管效率明显,实践中很少在正在进行的试验中新增治疗组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite its assessment, greatly reducing the time to reach the primary outcome compared to running a separate trial and without compromising the validity of the research or the ability to recruit to the trial and report the outcomes. The methodological and practical issues are presented, describing how they were addressed to ensure the amendment was a success. METHODS: FLAIR was designed as a two-arm trial requiring 754 patients. In stage 2, two new arms were added: a new experimental arm and a second control arm to protect the trial in case of a change in practice. In stage 3, the original experimental arm was closed as its planned recruitment target was reached. In total, 1516 participants will be randomised to the trial. RESULTS: The changes to the protocol and randomisation to add and stop arms were made seamlessly without pausing recruitment. The statistical considerations to ensure the results for the original and new hypotheses are unbiased were approved following peer review by oversight committees, Cancer Research UK, ethical and regulatory committees and pharmaceutical partners. These included the use of concurrent comparators in case of any stage effect, appropriate control of the type I error rate and consideration of analysis methods across trial stages. The operational aspects of successfully implementing the amendments are described, including gaining approvals and additional funding, data management requirements and implementation at centres. CONCLUSIONS: FLAIR is an exemplar of how an emerging experimental therapy can be assessed within an existing trial structure without compromising the conduct, reporting or validity of the trial. This strategy offered considerable resource savings and allowed the new experimental therapy to be assessed within a confirmatory trial in the UK years earlier than would have otherwise been possible. Despite the clear efficiencies, treatment arms are rarely added to ongoing trials in practice. This paper demonstrates how this strategy is acceptable, feasible and beneficial to patients and the wider research community. TRIAL REGISTRATION: ISRCTN Registry ISRCTN01844152 . Registered on August 08, 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Howard DR, Hockaday A, Brown JM, et al. A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials. 2021. PMID: 33419469. doi:10.1186/s13063-020-04971-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。